Biodexa Pharmaceuticals Plc
BDRX
$7.45
-$0.06-0.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 6.09% | 12.88% | 16.97% | 14.81% | 12.40% |
| Total Depreciation and Amortization | -3.58% | -6.82% | -7.56% | -6.05% | -5.05% |
| Total Amortization of Deferred Charges | -31.58% | -31.58% | -31.58% | -40.74% | 8.57% |
| Total Other Non-Cash Items | -2,061.18% | -7,011.41% | -10,464.02% | -1,073.25% | 71.33% |
| Change in Net Operating Assets | -164.03% | -475.15% | -7,195.29% | -837.19% | -254.98% |
| Cash from Operations | -42.33% | -60.69% | -85.20% | -46.48% | -9.67% |
| Capital Expenditure | 48.19% | 56.81% | 64.00% | 45.25% | 29.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -72.22% | -61.54% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 82.60% | 40.51% | -142.66% | -308.10% | -585.74% |
| Cash from Investing | 81.81% | 40.74% | -126.05% | -274.25% | -512.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -74.19% | -36.36% | 1.06% | 4.12% | 7.00% |
| Issuance of Common Stock | 1.05% | -12.90% | -24.98% | 4.13% | 56.82% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 54.12% | 54.52% | 54.91% | -36.65% | -1,596.94% |
| Cash from Financing | 18.33% | -0.65% | -13.93% | 5.73% | 38.23% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -476.36% | -287.08% | -242.48% | -320.91% | 82.24% |